Bisantrene - Moligand™, ≥98% , DNA disrupting agent, CAS No.78186-34-2, DNA disrupting agent
In stock
SKU
B649888
Bisantrene promots DNase I cleavage at oligopurine-oligopyrimidine tracts and slightly reduces the cleavage activity at alternating purine-pyrimidine sequences. ?\nBisantrene is an inhibitor of [ 3 H]uridine incorporation into RNA and [ 3 H]thymidine incorporation into DNA. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Bisantrene is an antitumor agent active against a number of experimental tumors, including P388 leukemia, L1210 leukemia, Lieberman plasma cell tumor, B16 melanoma, colon tumor 26, and Ridgway osteogenic sarcoma. ?\nBisantrene is effective over a dose range of 1.56 to 150 mg/kg depending upon the frequency, route, and schedule of the treatment and the tumor model used. ?\nBisantrene (25, 50 and 100 mg/kg; i.p.; once) pretreats with macrophages shows antitumor effect to mice with P815 tumor cells injection. ?\nBisantrene (10-150 mg/kg; i.v.; once) dose-dependently induces leukopenia in Neo mice. B cells and macrophages are targets for bisantrene toxicity. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:Topoisomerase II
More Information
| CAS | 78186-34-2 |
|---|---|
| Synonyms | Bisantrenum | 2-Benzylsuccinic acid # | AC-35847 | 9,10-Anthracenedicarboxaldehyde, bis(4,5-dihydro-1H-imidazol-2-ylhydrazone),dihydrochloride | 9,10-Bis((2-(4,5-dihydro-1H-imidazol-2-yl)hydrazono)methyl)anthracene | 9,10-Anthracenedicarboxaldehyde bis(2- |
| Specifications & Purity | Moligand™, ≥98% |
| Storage | Store at -20°C |
| Shipped In | Ice chest + Ice pads |
| Product Description | Bisantrene promots DNase I cleavage at oligopurine-oligopyrimidine tracts and slightly reduces the cleavage activity at alternating purine-pyrimidine sequences. ?\nBisantrene is an inhibitor of [ 3 H]uridine incorporation into RNA and [ 3 H]thymidine incorporation into DNA. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Bisantrene is an antitumor agent active against a number of experimental tumors, including P388 leukemia, L1210 leukemia, Lieberman plasma cell tumor, B16 melanoma, colon tumor 26, and Ridgway osteogenic sarcoma. ?\nBisantrene is effective over a dose range of 1.56 to 150 mg/kg depending upon the frequency, route, and schedule of the treatment and the tumor model used. ?\nBisantrene (25, 50 and 100 mg/kg; i.p.; once) pretreats with macrophages shows antitumor effect to mice with P815 tumor cells injection. ?\nBisantrene (10-150 mg/kg; i.v.; once) dose-dependently induces leukopenia in Neo mice. B cells and macrophages are targets for bisantrene toxicity. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:Topoisomerase II |
| Pubchem Sid | 528763584 |
| Solubility | DMSO : 1 mg/mL (2.51 mM; ultrasonic and warming and heat to 80°C) H2O : 0.1 mg/mL (0.25 mM; ultrasonic and warming and heat to 50°C) |
| PubChem CID | 5351322 |
| Molecular Formula | C22H22N8 |
Reviews
Customer Reviews
We found other products you might like!
-
Bisantrene dihydrochlorideStarting at €96.23
Remind me later